Analysis Tools
neoplasm
|
• treatment with adenoviral Cre to induce oncogenic Kras expression results in lung tumor development, but causes a lower tumor burden and decreased overall tumor area compared to induced mutants on a Spry2-null background
(J:119477)
• 20% and 100% of mice develop lung lesions at 6 weeks and 20 weeks, respectively, post intranasal adenoviral cre administration
(J:216266)
• all mice delivered with an adenovirus expressing cre recombinase through nasal inhalation at 8 weeks of age develop lung tumors
(J:299900)
|
|
• mice develop lung adenomas with a few adenocarcinomas following intratracheal administration of an adenovirus expressing Cre (Ad-Cre)
(J:207982)
• treatment with MLN4924, a small molecular inhibitor of NAE, beginning at 13 weeks after Ad-Cre administration reduces tumor burden, with a reduction in both number of hyperplastic areas and adenomas and size of the tumors
(J:207982)
• mice intratracheally administered an adenovirus expressing cre recombinase (Ad-cre) develop multiple lung adenomas
(J:333347)
|
|
• a few adenocarcinomas develop in mice following Ad-Cre administration
(J:207982)
• mice intratracheally administered Ad-cre develop a few adenocarcinomas
(J:333347)
|
respiratory system
|
• treatment with adenoviral Cre to induce oncogenic Kras expression results in lung tumor development, but causes a lower tumor burden and decreased overall tumor area compared to induced mutants on a Spry2-null background
(J:119477)
• 20% and 100% of mice develop lung lesions at 6 weeks and 20 weeks, respectively, post intranasal adenoviral cre administration
(J:216266)
• all mice delivered with an adenovirus expressing cre recombinase through nasal inhalation at 8 weeks of age develop lung tumors
(J:299900)
|
|
• mice develop lung adenomas with a few adenocarcinomas following intratracheal administration of an adenovirus expressing Cre (Ad-Cre)
(J:207982)
• treatment with MLN4924, a small molecular inhibitor of NAE, beginning at 13 weeks after Ad-Cre administration reduces tumor burden, with a reduction in both number of hyperplastic areas and adenomas and size of the tumors
(J:207982)
• mice intratracheally administered an adenovirus expressing cre recombinase (Ad-cre) develop multiple lung adenomas
(J:333347)
|
|
• a few adenocarcinomas develop in mice following Ad-Cre administration
(J:207982)
• mice intratracheally administered Ad-cre develop a few adenocarcinomas
(J:333347)
|
mortality/aging
|
• mice intratracheally administered Ad-cre have a median survival time of approximately 130 days with 100% death by 175 days
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| lung cancer | DOID:1324 |
OMIM:211980 OMIM:608935 OMIM:612571 OMIM:612593 OMIM:614210 |
J:207982 | |
